Fund moves
4.6%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Planned for Nov 12, 2026 · Notice filed Nov 12, 2026
A Ligand Pharmaceuticals director told the SEC about a plan to sell $636K of Ligand Pharmaceuticals shares around Nov 12, 2026. The filing says the shares were acquired as compensation.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
None found in footnotes
Only flagged when a footnote says so; never inferred
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Insider selling
Traded Nov 12 · filed 4 days laterNot reported under a pre-arranged trading plan
A Ligand Pharmaceuticals director sold $636K of Ligand Pharmaceuticals shares. The filing does not indicate a pre-arranged trading plan.
John W Kozarich (Director) sold ~$163K of Ligand Pharmaceuticals, Inc.
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.